• TransCode Therapeutics executed a waiver with Yorkville tied to its April 6 Standby Equity Purchase Agreement financing.
• Waiver required a prepayment of 840,975, including 759,000 principal, 75,900 prepayment premium, 6,075 accrued interest.
• Yorkville waived any Amortization Event through Oct. 31, 2026, triggered by VWAP below the $1.72 floor price.
• Payment made Oct. 1, 2026; remaining aggregate principal outstanding under the convertible notes is about $4.1 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-112826), on October 01, 2026, and is solely responsible for the information contained therein.